Table 4.

Odds ratios (and 95% confidence intervals) for developing gastric cancer, by time from baseline to cancer diagnosis, gastrin and CCK continuous (log-transformed)

		Gastrin: continuous			Cholecystokinin: continuous
	N cases	ORa	95% CI	N cases	ORa	95% CI
Gastric cancera
< 5 years	54	0.97	0.69, 1.35	24	0.49	0.34, 0.71
5–10 years	108	1.19	0.94, 1.51	87	1.09	0.86, 1.38
> 10 years	166	1.41	1.15, 1.72	153	0.75	0.64, 0.89
Gastric non-cardia adenocarcinomab
< 5 years	42	0.77	0.52, 1.14	19	0.54	0.36, 0.81
5–10 years	81	1.24	0.95, 1.63	64	1.08	0.82, 1.41
> 10 years	122	1.55	1.24, 1.95	117	0.74	0.62, 0.89
Oesophagogastric junctional adenocarcinomab
< 5 years	10	0.72	0.33, 1.59	4	0.37	0.14, 0.98
5–10 years	24	0.73	0.43, 1.22	20	1.11	0.69, 1.77
> 10 years	41	0.91	0.60, 1.37	33	0.79	0.57, 1.11

¹Adjusted for: age at randomization.

^bGastric carcinoid tumours were not included in this analysis because of small numbers (so that GNCA and EGJA case numbers will not sum to gastric cancer numbers).